← Back to Search

Nanoparticle-drug Conjugate

EP0057 for Ovarian Cancer

Phase 2
Waitlist Available
Research Sponsored by Ellipses Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 18 months
Awards & highlights

Study Summary

This trial is testing a new drug, EP0057, to see if it can improve responses in ovarian cancer when combined with another drug, Olaparib.

Eligible Conditions
  • Ovarian Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients with related treatment emergent adverse events as assessed by NCI CTCAE version 5
Number of patients with serious adverse events
Number of patients with treatment emergent adverse events as assessed by NCI CTCAE version 5
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Phase 2A Cohort 2Experimental Treatment2 Interventions
Patients with advanced ovarian cancer who have received at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by a PARP inhibitor as maintenance treatment as their last treatment regimen
Group II: Phase 2A Cohort 1Experimental Treatment2 Interventions
Patients with advanced platinum resistant ovarian cancer who have received no more than 1 prior line of therapy which must be platinum-based chemotherapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EP0057
2020
Completed Phase 2
~40
Olaparib tablets
2020
Completed Phase 2
~100

Find a Location

Who is running the clinical trial?

Ellipses PharmaLead Sponsor
4 Previous Clinical Trials
443 Total Patients Enrolled
James SandyStudy Directorjames@ellipses.life

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many medical facilities are presently conducting this experiment?

"11 medical centres that have been authorised to recruit participants for this trial are located in Irvine, Boston and Charlottesville plus 8 other sites. For the sake of convenience, it is suggested that prospective patients select their closest location when joining the program."

Answered by AI

Is this research venture unprecedented?

"EP0057 has been under investigation since 2005 when AstraZeneca first sponsored the initial research. Following those 98 participants, Phase 1 approval was granted and it is now being evaluated in 188 trials across 1468 cities and 59 countries."

Answered by AI

What medical conditions is EP0057 commonly employed to alleviate?

"EP0057 is a potential course of action for individuals suffering from advance directives, malignant neoplasm of the ovaries and primary peritoneal cancer."

Answered by AI

What prior investigations have been done related to EP0057?

"Initially researched in 2005, EP0057 has been studied 63 times with positive results. At present, 188 active trials are taking place; a considerable portion of these experiments occurring at the Irvine research centre in California."

Answered by AI

Has registration for this medical trial opened yet?

"Currently, this clinical trial is not accepting any more participants. Initially posted on December 14th 2020 and last updated November 1st 2022, it's worth noting that there are 677 other medical studies recruiting patients with ovarian cancer and 188 trials for EP0057 actively seeking individuals to take part in the research."

Answered by AI

Is EP0057 a viable treatment option with minimal risks to patients?

"With limited clinical data concerning its efficacy, EP0057 was given a safety rating of 2. Nonetheless, there is evidence that the drug has some level of safety as it is currently in Phase II trials."

Answered by AI

What is the aggregate figure of participants for this medical experiment?

"At this time, sadly there is no recruitment for EP0057. This research was first posted on December 14th 2020 and edited lastly on November 1st 2022. Thankfully, if you are scouring other trials, 677 studies pertaining to ovarian cancer and 188 trials concerning EP0057 are now accepting participants."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
EP0057 in Combination With Olaparib in Advanced Ovarian Cancer
2020. "EP0057 in Combination With Olaparib in Advanced Ovarian Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04669002.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top